comparing and sequencing t-dm1 and t-dxd in her2 breast cancer
Published 5 months ago • 124 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
1:08
updated survival results of destiny-breast03: t-dxd vs t-dm1 in her2 metastatic breast cancer
-
1:46
choosing between tucatinib and t-dxd in her2 breast cancer
-
1:08
destiny-breast02: t-dxd in her2 metastatic breast cancer previously treated with t-dm1
-
1:20
updated results of destiny-breast03: t-dxd vs t-dm1 in metastatic her2 breast cancer
-
2:48
destiny-breast03: t-dxd is superior to t-dm1 in her2 metastatic breast cancer
-
2:52
5-year correlative analysis of atempt: adjuvant t-dm1 vs paclitaxel trastuzumab for stage i her2 bc
-
3:25
new data comparing adjuvant t-dm1 vs trastuzumab for her2 breast cancer
-
0:59
sequencing her2-targeted therapies in breast cancer
-
0:53
tuxedo-1: t-dxd for patients with her2-positive breast cancer and brain metastasis
-
4:15
debbrah: t-dxd in her2 or her2-low advanced breast cancer with cns involvement
-
3:09
destiny-breast02: high levels of efficacy of t-dxd in previously treated her2 breast cancer
-
3:51
adjuvant t-dm1 therapy for early-stage her2 breast cancer
-
1:23
tuxedo-1: qol and neurocognitive function in her2-positive bc w/ brain metastasis treated with t-dxd
-
2:44
sequencing agents for her2 metastatic breast cancer
-
1:36
phase 3 trial investigates t-dm1 and pertuzumab in her2 breast cancer
-
1:16
her2climb-04: tucatinib plus t-dxd for her2 breast cancer
-
5:15
case review: t-dm1 for residual her2 breast cancer
-
3:32
sequencing novel her2-targeted therapies in metastatic breast cancer
-
1:21
dr. louis weiner discusses the t-dm1 emilia trial for her2-positive breast cancer